



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Elenestinib

Cat. No.:	HY-152839
CAS No.:	2505078-08-8
Molecular Formula:	C ₂₇ H ₂₉ FN ₁₀ O
Molecular Weight:	528.58
Target:	c-Kit
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (236.48 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	1.8919 mL	9.4593 mL	18.9186 mL	
		5 mM	0.3784 mL	1.8919 mL	3.7837 mL	
		10 mM	0.1892 mL	0.9459 mL	1.8919 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline					
	Solubility: ≥ 6.25 mg/mL (11.82 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Elenestinib (BLU-263) is a potent and orally active tyrosine kinase inhibitor. Elenestinib has the potential for the research of systemic mastocytosis (SM). Elenestinib inhibits KIT D816V with an IC ₅₀ value of 0.2 nM ^{[1][2]} .
IC ₅₀ & Target	IC50: 0.2 nM (KIT D816V) ^[2]

REFERENCES

- [1]. Mariana Castells, et al. A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome. Allergy and Clinical Immunology. 2022, 149 (2).
- [2]. Dave N, et al. Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteers[C]//Cancer Res (AACR Annual Meeting Abstracts). 2021, 122.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA